HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bloomgarden, Z. T. Search for Related Content PubMed PubMed Citation Articles by Bloomgarden, Z. T. Social Bookmarking                What's this?

Obesity, Hypertension, and Insulin Resistance

Abbreviations: ACEI, angiotensin-converting enzyme inhibitor • ADA, American diabetes Association • ADMA, asymmetric dimethyl arginine • ARB, angiotensin receptor blocker • ASH, American Society of Hypertension • ATP, Adult Treatment Panel • BAT, brown adipose tissue • BP, blood pressure • CHD, coronary heart disease • CHF, congestive heart failure • CVD, cardiovascular disease • ESRD, end-stage renal disease • FA, free fatty acid • HOT, Hypertension Optimal Treatment • IDL, intermediate density lipoprotein • IFG, impaired fasting glucose • IGT, impaired glucose tolerance • IRS, insulin resistance syndrome • LCAT, lecithin-cholesterol acyl transferase • LPL, lipoprotein lipase • NASH, nonalcoholic steatohepatitis • NHANES, National Health and Nutrition Examination Survey • PCOS, polycystic ovary syndrome • RGZ, rosiglitazone • SC, subcutaneous • SNS, sympathetic nervous system • SSPG, steady-state plasma glucose • TNF, tumor necrosis factor • UKPDS, U.K. Prospective Diabetes Study • WHO, World Health Organization

The first 300 words of the full text of this article appear below.

This article summarizes material presented at the meeting of the American Society of Hypertension (ASH) in New York, New York, May, 2002, as well as presentations at the American Diabetes Association (ADA) Annual Meeting in San Francisco, California, June, 2002. At a symposium addressing the relationships between obesity, hypertension, and cardiovascular disease at the ASH, Roger Unger (Dallas, TX) discussed lipotoxicity and the metabolic syndrome. He pointed out that over that past 50 years there has been a great change in the food environment, so that the "mechanism for preloading calories, storing them for when a famine occurred," has led to "hypertrophy and hyperplasia of those adipocytes [...]. Famines were eliminated and replaced by a never-ending stream of high-quantity, high-fat, high-carbohydrate foods at the same time that physical exertion dropped to an all-time low." This has led to a progressive increase in obesity, particularly over the past two decades. "As long as the excess fat remains in the adipocyte," he stated, "health is not deleteriously affected," but an "increase in ectopic deposition of lipids" causes the insulin-resistant state, with insulin resistance per se characterized by Unger as "not the proximal cause of the syndrome." Unger examined monogenic disorders of lack of leptin action to understand "the mechanism of the disorder." These syndromes, which lead to components of the metabolic syndrome, suggest that leptin resistance or deficiency may be a more central cause than insulin resistance.

The normal actions of leptin can be seen in animal models of obesity, with overfeeding leading to hyperleptinemia, which may cause fat to deposit primarily in the adipocyte. Normal islets, as an example, "fill up with triglycerides" when incubated with fatty acids, but this can be prevented by administration of leptin. When leptin action is insufficient, as seen in the fatty/fatty (fa/fa) rat . . . [Full Text of this Article]

Hypertension and diabetes

Management of the metabolic syndrome

Insulin resistance

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?